Transitions and pharmaceutical use by CDR level in Alzheimers disease.

 
   Lead Investigator:    Eldon Spackman
   Institution      :    University of Washington
   E-Mail           :    spackman@u.washington.edu
   Proposal ID      :    78


   Publications:


1  Bloudek L, Spackman E, Sullivan SD
   A Comparison of Transitions between Health States and Institutionalization among AD Patients vs Non-AD Dementia Patients Using the NACC-UDS Database
   Abstract  Value Health,13:A108-A109,2010,

   PUBLISHED



2  Bloudek LM, Spackman DE, Veenstra DL, Sullivan SD
   CDR State Transition Probabilities in Alzheimer's Disease with an without Cholinesterase Inhibitor Intervention in an Observational Cohort
   Journal Article  J Alzheimers Dis,24:599-607,2011,PMC3593724

   PUBLISHED



3  Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD
   Measuring Alzheimer disease progression with transition probabilities: Estimates from NACC-UDS
   Journal Article  Curr Alzheimer Res,9:1050-1058,2012,PMC3690579

   PUBLISHED





   Proposal Description:
   Specific Aims  Specific Aim 1:  To determine AD patient transition probabilities between severities as measured by the Clinical Dementia Rating Scale.      Specific Aim 2:  To determine nursing home transition probabilities by disease severity and other patient and caregiver characteristics.      Specific Aim 3:  To determine the pharmaceutical use of AD patients by disease severity (CDR level) and other patient characteristics (age, sex, caregiver status, living arrangement, center and education).